Flurbiprofen response
- Synonyms
- Ansaid response; Ocufen response
Summary
Available tests
Clinical tests (9 available)
Molecular Genetics Tests
Therapeutic recommendations
From Medical Genetics SummariesThis section contains excerpted1information on gene-based dosing recommendations. Neither this section nor other parts of this review contain the complete recommendations from the sources.
2017 Statement from the US Food and Drug Administration (FDA)
In patients who are known or suspected to be poor CYP2C9 metabolizers based on genotype or previous history/experience with other CYP2C9 substrates (such as warfarin and phenytoin), reduce the dose of flurbiprofen to avoid abnormally high plasma levels due to reduced metabolic clearance.
Please review the complete therapeutic recommendations that are located here:(1)
1 The FDA labels specific drug formulations. We have substituted the generic names for any drug labels in this excerpt. The FDA may not have labeled all formulations containing the generic drug.
- DailyMed Drug Label, 2021DailyMed Drug Label, FLURBIPROFEN, 2021
- DailyMed Drug Label, 2016DailyMed Drug Label, flurbiprofen, 2016
IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.